KYNTRA BIO, INC.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
KYNB$3.57-8.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
(In thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net income (loss) | $183,452 | $(47,579) |
| Other comprehensive income (loss): | ||
| Foreign currency translation adjustments | (1,966) | 1,166 |
| Cumulative currency translation adjustment attributable to divestiture | 5,479 | — |
| Unrealized gain (loss) on investments, net of tax effect | 37 | (23) |
| Other comprehensive income, net of taxes | 3,550 | 1,143 |
| Comprehensive income (loss) | 187,002 | (46,436) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.